Tumor immunology and immunotherapy. Ed. Robert C. Rees. Oxford University Press (2014)
- Adaptive Tcell immunity and tumor antigen recognition
- Impact of ageing and body mass on cancer immunotherapy outcomes
- The potential of natural killer cells in cancer immunotherapy
- The tumor microenvironment: The role of tumorassociated macrophages in cancer progression and responses to therapy
- ‘Hard’ and ‘soft’ loss of MHC class I expression in cancer cells
- Modulation of the adaptive immune system through chronic inflammation and Tregulatory responses
- Myeloid-derived suppressor cells: Immune-suppressive cells that facilitate tumor progression and promote and deter cancerassociated inflammation
- Triggering death receptors to promote cancer cell death
- Identification of tumor antigens for clinical evaluation
- Viral antigens as targets for prophylactic and therapeutic intervention in cancer
- HER2/neu as a target for vaccine and antibodydirected therapies
- Preclinical evaluation of immunotherapy: The case for prostate cancer and the TRAMP model
- Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy
- Predictive biomarkers to better select patients for cancer immunotherapy
- Viral platforms for expression of tumor antigens in cancer immunotherapy
- Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies
- DNA vaccines
- Programming the immune system through childhood infections: MUC1 tumorassociated antigen (TAA) as a diseaseassociated antigen (DAA)
- Vaccination against myeloid leukaemias using newly defined antigens
- Immunecheckpoint blockade in cancer immunotherapy
- Multipeptide cancer vaccines for clinical application
- Adoptive Tcell therapy using TILs for the treatment of metastatic melanoma
- Chimeric antigen receptor gene therapy in cancer
- The vaccinal effect of monoclonal antibodies in cancer therapy
- Antibody therapies: defining appropriate cell surface epitopes for targeting tumors
- Adoptive lymphocyte (stem cell) therapy in cancer
- Cancer stem cells (CSCs) and epithelialtomesenchymal transition (EMT): Tumor cell plasticity challenges immunotherapy
- Immune escape and ageing of the immune system compromises the immune response to tumor antigens
[contact-form-7 id=»5168″ title=»Контактная форма 1″]